Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

达拉图穆马 医学 来那度胺 内科学 临床终点 硼替佐米 多发性骨髓瘤 耐火材料(行星科学) 地塞米松 人口 临床研究阶段 不利影响 肿瘤科 恶心 外科 临床试验 物理 环境卫生 天体生物学
作者
Verónica González‐Calle,Paula Rodríguez‐Otero,Anna Sureda,Felipe de Arriba,Marta Reinoso,Paz Ribas,Ana Pilar González-Rodríguez,Yolanda Campos,Albert Oriol,Joaquín Martínez‐López,Marta Sonia González,Miguel‐Teodoro Hernández,Maialen Sirvent,María‐Teresa Cedena,Noemí Puig,Bruno Paiva,Joan Bladé,Juan José Lahuerta,Jesús F. San Miguel,María‐Victoria Mateos
出处
期刊:Haematologica [Ferrata Storti Foundation]
被引量:1
标识
DOI:10.3324/haematol.2023.284089
摘要

The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd (S-DVd). A total of 57 patients were enrolled in the two parts of the study. Part 1 enrolled a heavily pretreated population with at least 3 prior lines of therapy and part 2 enrolled an early relapse population with at least 1 prior therapy. The primary endpoint was complete response (CR) rate in part 2 and overall response rate (ORR) in part 1. In the latter, 24 patients were treated with a median of 3 prior lines. Overall response rate (ORR) was 50% with 2 CR. Median progressionfree survival (PFS) was 7 months. In part 2, 33 patients were enrolled, with a median of 1 prior lines. ORR was 82% and CR or better was 33%. Median PFS was 24 months. In lenalidomide refractory patients, a median PFS of 22.1 months was observed. Thrombocytopenia was the most common hematological adverse event (69%; grade 3-4: 34%) and nausea, the most frequent nonhematological AE (38%; grade 3-4: 6%). 62% of the patients required dose modifications. In summary, although the primary endpoint of the study was not met, the combination of S-DVd showed encouraging clinical efficacy with a generally manageable safety profile representing a potential option for the treatment of RRMM patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
辛勤香岚完成签到,获得积分10
刚刚
Vicky完成签到 ,获得积分10
1秒前
Fxxkme发布了新的文献求助10
1秒前
平淡的寄风完成签到,获得积分10
3秒前
公西翠萱完成签到,获得积分10
5秒前
WYJie完成签到,获得积分10
8秒前
挪威的森林完成签到,获得积分10
8秒前
addi111完成签到,获得积分10
8秒前
justsayit完成签到 ,获得积分10
9秒前
炙热的宛完成签到,获得积分10
9秒前
仿真小学生完成签到,获得积分10
9秒前
10秒前
诚心代芙完成签到 ,获得积分10
10秒前
简单的平松完成签到,获得积分10
10秒前
碧蓝雁风完成签到 ,获得积分10
11秒前
慕青应助顺心的水云采纳,获得10
12秒前
李L完成签到,获得积分10
13秒前
竹得风完成签到 ,获得积分10
14秒前
15秒前
景平完成签到,获得积分10
15秒前
尽快看看完成签到 ,获得积分10
15秒前
neverever完成签到,获得积分10
16秒前
和谐的夏岚完成签到 ,获得积分10
17秒前
meehan完成签到,获得积分10
17秒前
18秒前
是容许鸭发布了新的文献求助10
18秒前
yinxx完成签到,获得积分10
19秒前
114555完成签到,获得积分10
19秒前
20秒前
烟花应助傻死一只橙子采纳,获得10
20秒前
重要山彤完成签到 ,获得积分10
21秒前
wjw完成签到,获得积分10
22秒前
科研菜鸟完成签到 ,获得积分10
23秒前
一白完成签到 ,获得积分10
23秒前
asenda完成签到,获得积分0
24秒前
boxi完成签到,获得积分10
24秒前
Ade完成签到,获得积分10
25秒前
25秒前
贪玩手链完成签到 ,获得积分10
26秒前
imp完成签到 ,获得积分10
26秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134060
求助须知:如何正确求助?哪些是违规求助? 2784861
关于积分的说明 7769049
捐赠科研通 2440325
什么是DOI,文献DOI怎么找? 1297361
科研通“疑难数据库(出版商)”最低求助积分说明 624959
版权声明 600792